News

FDA Approves Pfizer’s IBRANCE for HR+, HER2+ Metastatic Breast Cancer

The US Food and Drug Administration (FDA) has approved Pfizer’s IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as a maintenance treatment for adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. IBRANCE is an oral inhibitor of […]